When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OMER - Omeros's Biologics nabs accelerated review in U.S. for Narsoplimab
Omeros Corporation
Under Priority Review status, the FDA accepts Omeros's (OMER) Biologics License Application ((BLA)) for Narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The FDA has set target action date of July 17.FDA also indicated in its filing letter that the agency is not currently planning to hold an advisory committee meeting to discuss the BLA. OMER +3.4% premarket to $18.69Source: Press Release